All In Biotech

Drug Trial Radar · NCT02163577

Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)

A Randomized, Open-Label, Dose Finding, Phase 2 Study to Assess the Pharmacodynamics and Safety of the Anti-FGF23 Antibody, KRN23, in Pediatric Patients With X-linked Hypophosphatemia (XLH)

Last checked: Nov 20, 2026Latest source record: May 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

52

Actual

Start

Jul 2, 2014

Primary completion

Oct 30, 2018

Study completion Oct 30, 2018

Sponsor

Lead sponsor
Kyowa Kirin, Inc.Industry
Sponsor type
Industry
Collaborators
Kyowa Kirin Co., Ltd.
First posted
Jun 13, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 5 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of the study are to: * Identify a dose and dosing regimen of burosumab, based on safety and pharmacodynamic (PD) effect, in pediatric XLH participants * Establish the safety profile of burosumab for the treatment of children with XLH including ectopic mineralization risk, cardiovascular effects, and immunogenicity profile * Characterize the pharmacokinetic (PK)/PD profile of the KRN23 doses tested in the monthly (Q4) and biweekly (Q2) dose regimens in pediatric XLH patients * Determine the PD effects of burosumab treatment on markers of bone health in pediatric XLH patients * Obtain a preliminary assessment of the clinical effects of burosumab on bone health and deformity, muscle strength, and motor function * Obtain a preliminary assessment of the effects of burosumab on participant-reported outcomes, including pain, disability, and quality of life in pediatric XLH patients * Evaluate the long-term safety and efficacy of burosumab

Conditions

  • X-linked Hypophosphatemia

Interventions

  • burosumabBiological

    solution for SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in RSS Total Score Over TimeTime frame: Baseline, Week 40, 64, 160
  2. Change From Baseline in Serum Phosphorus Over TimeTime frame: Baseline, Week 40, 64, 160
  3. Change From Baseline in Serum 1,25(OH)2D Over TimeTime frame: Baseline, Week 40, 64, 160
  4. Change From Baseline in TmP/GFR Over TimeTime frame: Baseline, Week 40, 64, 160

Locations

9 sites in 4 countries. Site status is shown where the registry gives one.

  • University of California San Francisco

    San Francisco, California

  • Yale University School of Medicine

    New Haven, Connecticut

  • Indiana University Hospital

    Indianapolis, Indiana

  • Shriners Hospital for Children

    St Louis, Missouri

  • Bicetre Hospital

    Le Kremlin-Bicêtre, France

  • University Medical Center Groningen

    Groningen, Netherlands

  • Birmingham Children's University

    Birmingham, United Kingdom

  • Great Ormond Street Hospital

    London, United Kingdom

  • Royal Manchester Hospital

    Manchester, Lancashire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.